OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goldman on the Use of Immunotherapy in Oncogene-Driven NSCLC

March 25th 2020

Jonathan W. Goldman, MD, health sciences clinical instructor, Department of Medicine, and Hematology/Oncology member, Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program, UCLA, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer (NSCLC).

Dr. Husain on Ongoing Research Evaluating Plasma-Based Testing in Lung Cancer

March 25th 2020

Hatim Husain, MD, medical oncologist and associate professor of medicine, Moores Cancer Center, University of California, San Diego (UCSD), discusses ongoing research efforts evaluating plasma-based testing in lung cancer.

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

March 25th 2020

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Dr. Abdul Hay on Evaluation of Transplant Eligibility in ALL

March 25th 2020

Mohammad Maher Abdul Hay, MD, discusses the process of evaluating the eligibility of patients with acute lymphoblastic leukemia for transplant.

Dr. Saint Fleur-Lominy on the Use of Ruxolitinib Versus Fedratinib in MPNs

March 25th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms.

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

March 25th 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

Dr. Kahl on Treatment Strategies for Indolent Lymphoma

March 25th 2020

Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.

Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias

March 25th 2020

Jerald P. Radich, MD, discusses the impact of minimal residual disease in patients with acute versus chronic leukemias.

Dr. Grossbard on the Role of MRD in Follicular Lymphoma

March 24th 2020

Michael L. Grossbard, MD, discusses the role of minimal residual disease in follicular lymphoma.

Dr. Cutler on Optimizing Treatment for Acute and Chronic GVHD

March 24th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses methods to optimize treatment for patients with acute and chronic graft-versus-host disease.

Dr. Westin on Treatment Challenges in Large Cell Lymphoma

March 24th 2020

Jason Westin, MD, MS, FACP, discusses challenges with treating patients with large cell lymphoma.

Dr. Cortes on the Utility of Ruxolitinib in MPNs

March 23rd 2020

Jorge E. Cortes, MD, discusses the utility of ruxolitinib in myeloproliferative neoplasms.

Dr. Garcia on Unmet Need in Myelofibrosis

March 23rd 2020

Jacqueline S. Garcia, MD, discusses unmet needs for patients with myelofibrosis who progress on JAK inhibitors.

Dr. Jain on the Role of Allogeneic Transplant in Myelofibrosis

March 23rd 2020

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Dr. Cone on Evaluating the Relative Cardiac Risk of GnRH Agonists Versus Antagonists in Prostate Cancer

March 23rd 2020

Eugene B. Cone, MD, a urologic oncology fellow at Brigham and Women’s Hospital and Massachusetts General Hospital, discusses the methods that were used to evaluate the relative cardiac risk of gonadotropin-releasing hormone (GnRH) agonists versus antagonists in patients with prostate cancer.

Dr. Graff on the KEYNOTE-641 Trial in mCRPC

March 23rd 2020

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hurvitz on Reducing Potential Exposure to COVID-19

March 23rd 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the steps that can be taken to reduce potential exposure to coronavirus disease 2019 (COVID-19).

Dr. Overman on Second-Line Therapy Options for Colorectal Cancer

March 23rd 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

March 23rd 2020

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

Dr. Tripathy on Known Elements of COVID-19

March 21st 2020

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses known elements of COVID-19.